Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Caterpillar fungus could hold key to new osteoarthritis treatments
The caterpillar fungus Cordyceps militaris could hold the key to new treatments for osteoarthritis.

Active compound can reduce pain and halt disease progression

A fungus that infects caterpillars, Cordyceps militaris, could hold the key to new treatments for osteoarthritis, according to new research.

The study, published in the journal Scientific Reports, suggests that an active compound in the fungus, cordycepin, could reduce pain and halt disease progression.

Scientists say it works by blocking inflammation in an entirely different way to any other pain killer - by repressing a process called polyadenylation - and could be used to help patients for which other treatments have failed.

The study was led by the University of Nottingham and funded by the charity ‘Versus Arthritis’.

“We hope that cordycepin will prove to be the founder of a new class of pain killer,” explained Dr Cornelia De Moor from the University of Nottingham’s School of Pharmacy. “There is a long way to go before a cordycepin-derived medicine reaches patients, but our work is very promising, we are very excited about the prospects.”

Previous work by the University of Nottingham found that cordycepin had anti-inflammatory effects in both cartilage and bone. In this study, researchers administered the compound to rats and mice with osteoarthritis and found that it both reduced pain behaviour and structural damage.

Interestingly, researchers found that cordycepin blocked the inflammation by affecting the last stage of making a messenger RNA, Polyadenylation.

Current treatment options for osteoarthritis are limited to lifestyle changes and reducing pain with non-steroidal anti-inflammatories or opioids. But these have limited efficacy and come with unpleasant side effects.

The team hope that the results from this new research will provide a more effective treatment for osteoarthritis that is less toxic and will, therefore, have fewer side effects for patients.

Dr Stephen Simpson from Versus Arthritis said: “Although in its early stages, the study has great potential suffering pain of musculoskeletal conditions and demonstrated the high value and impact of novel discovery-led research on understanding and treating diseases.”

Image (C) Jose Ramon Pato, Coruña, España.

Become a member or log in to add this story to your CPD history

RUMA CA&E extends survey deadline

News Story 1
 RUMA CA&E has extended the deadline for its online survey into vaccine availability.

Vets, SQPs, retailers and wholesalers will now have until Friday, 26 September at 5pm to submit their response.

The survey aims to further understanding into the vaccine supply challenges faced by the sector. It will also consider the short and long term impacts of disruption issues.

Insights are anonymous, and will be shared with industry stakeholders and government bodies.

The survey can be accessed here

Click here for more...
News Shorts
Dechra launches checklist for veterinary sustainability

Global animal health specialist Dechra has announced the world's first Veterinary Green Theatre Checklist (VGTC) to help make surgery more sustainable.

Endorsed by leading veterinary organisations, including the BEVA, BVNA and RCVS Knowledge, the checklist is designed to reduce the environmental footprint of veterinary care, while supporting better animal health outcomes.

The checklist was launched at the World Congress of Veterinary Anaesthesia and Analgesia in Paris and will be followed by an internal training and awareness campaign. For more information, visit dechra.com